세계 간질환 치료 시장 규모는 2024년 460억 달러에서 예측 기간 동안 7.1%의 CAGR로 성장하여 2030년에는 691억 달러에 달할 것으로 예상됩니다.
북미 시장은 2024년 208억 달러에서 예측 기간 동안 7.3%의 CAGR로 성장하여 2030년에는 316억 달러에 달할 것으로 예상됩니다. 아시아태평양 시장은 2024년 69억 달러에서 예측 기간 동안 CAGR 7.9%로 성장하여 2030년에는 108억 달러에 달할 것으로 예상됩니다.
세계의 간질환 치료 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 시장 규제 환경, 파이프라인 분석, 시장 규모 추정 및 예측, 각종 부문별·지역별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
제1장 주요 요약
시장 전망
조사 범위
시장 요약
제2장 시장 개요
개요
질환 및 제품별 치료 분류
간염
간종양·간암
자가면역성 간질환
알코올성 간질환
만성 간질환
비알코올성 지방간질환
거시경제 요인 분석
인구통계와 고령화
세계 경제 성장
지정학적 리스크, 무역 전쟁, 공급망 혼란
국민 의식 향상과 교육
Porter's Five Forces 분석
제3장 시장 역학
개요
시장 성장 촉진요인
간질환 발생률 증가
알코올 섭취와 부적절한 식사
백신의 제공과 의식 향상을 위한 정부 이니셔티브
시장 성장 억제요인
FDA 승인과 엄격한 정부 규제
약물 부작용과 리스크
시장 기회
치료 선택사항의 진보
신흥 시장과 치료 접근성
제4장 규제 상황
세계 규제기관
미국 식품의약국
유럽 의약품청
일본 의약품 의료기기 종합 기구
중국 국가 약품 감독 관리국
간 약물 개발에 관한 인사이트
제5장 최신 동향과 파이프라인 분석
최신 동향
간질환의 맞춤형 의료
간이식의 진보
재생의료와 줄기세포 치료
간암에 대한 면역요법
mRNA에 의한 간질환 수복
파이프라인 분석
특허 분석
조사 결과
제6장 시장 세분화 분석
세분화 내역
시장 내역 : 질병별
요약
간염
비알코올성 지방간질환
간세포암
자가면역성 간질환
알코올성 간질환(ALD)
만성 간질환
기타
지역적 내역
시장 내역 : 지역별
요약
북미
유럽
아시아태평양
남미
중동 및 아프리카
제7장 경쟁 정보
요약
주요 기업 순위
전략 분석
벤처 자금 조달과 투자
제8장 간질환 치료 산업의 지속가능성 : ESG 관점
개요
환경의 지속가능성
사회적 책임
거버넌스
ESG 리스크 평가
BCC에 의한 결론
제9장 부록
조사 방법
정보 출처
약어
기업 개요
ABBVIE INC.
ASTRAZENECA
BAYER AG
BIOTEST AG
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
GSK PLC.
INTERCEPT PHARMACEUTICALS INC.
MADRIGAL PHARMACEUTICALS
MERCK & CO. INC.
NOVARTIS AG
SALIX PHARMACEUTICALS
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
신흥 스타트업/시장 디스럽터
ksm
영문 목차
영문목차
The global market for liver disease treatments is estimated to increase from $46.0 billion in 2024 to reach $69.1 billion by 2030, at a compound annual growth rate (CAGR) of 7.1% from 2025 through 2030.
The North American market for liver disease treatments is estimated to increase from $20.8 billion in 2024 to reach $31.6 billion by 2030, at a CAGR of 7.3% from 2025 through 2030.
The Asia-Pacific market for liver disease treatments is estimated to increase from $6.9 billion in 2024 to reach $10.8 billion by 2030, at a CAGR of 7.9% from 2025 through 2030.
Report Scope:
This report on the global market for liver disease treatments provides qualitative and quantitative data on the current market dynamics. It discusses different liver diseases and their treatment modalities.
Analyses of the most frequently used products, clinical trials, new product approvals, and emerging technologies are also included. The demographics of the major regions-North America, Europe, Asia-Pacific, South America, and the Middle East and Africa-as well as their prospects for growth are summarized. The profiles of leading companies in the market and their strategies are also discussed.
The market for liver disease treatments is broken into hepatitis, non-alcoholic fatty liver disease (NAFLD), hepatocellular carcinoma, autoimmune liver diseases, alcohol-induced liver disease (ALD), chronic liver disease, and others. The growth potential and forecast data are discussed for each disease for the aforementioned regions and many countries.
The report includes global revenue in $ millions for the base year of 2024, estimates for 2025, and data for the forecast period of 2026 through 2030.
Report Includes :
52 data tables and 63 additional tables
Analyses of the trends in the global markets for liver disease treatments, with revenue data from 2023, estimates for 2024, forecasts for 2025, and projected CAGRs through 2029
Estimates of the size and revenue prospects for the global market, along with a market share analysis by product (drug) type, disease type, route of administration, end user, and region
Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables
Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
An assessment of the major drugs that can cause liver disease, the market's current situation and future prospects, clinical trials, new developments, and pipeline products
An analysis of the key patent grants and recently published patents
Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
Analysis of the industry structure, including companies' product offerings, strategic alliances, M&A activity, venture fundings and investment outlook
Company profiles of major players within the industry, including Gilead Sciences Inc., Bristol Myers Squibb Co., AbbVie Inc., and Merck & Co. Inc.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Classification of Therapies, by Disease and Product
Hepatitis
Liver Tumors and Liver Cancer
Autoimmune Liver Diseases
Alcohol-induced liver disease
Chronic Liver Disease
Non-Alcoholic Fatty Liver Disease
Analysis of Macroeconomic Factors
Population Demographics and Aging Population
Global Economic Growth
Geopolitical Risks, Trade Wars, and Supply Chain Disruptions
Public Awareness and Education
Porter's Five Forces
Potential for New Entrants (Moderate to Low)
Bargaining Power of Suppliers (Moderate to High)
Bargaining Power of Buyers (Moderate to High)
Threat of Substitute Products or Services (Low to Moderate)
Industry Competitiveness (High)
Chapter 3 Market Dynamics
Overview
Market Drivers
Increasing Incidence of Liver Diseases
Consumption of Alcohol and Improper Diet
Government Initiatives to Provide Vaccines and Grow Awareness
Market Restraints
FDA Approvals and Stringent Government Regulations
Side Effects and Risks Associated with Drugs
Market Opportunities
Advances in Treatment Options
Emerging Markets and Access to Treatment
Chapter 4 Regulatory Landscape
Global Regulatory Agencies
U.S. Food and Drug Administration
European Medicines Agency
Japan's Pharmaceuticals and Medical Devices Agency
China's National Medical Products Administration
Considerations in Liver Drug Development
Chapter 5 Emerging Trends and Pipeline Analysis
Emerging Trends
Personalized Medicine in Liver Disease
Advances in Liver Transplantation
Regenerative Medicine and Stem Cell Therapy
Immunotherapy for Liver Cancer
Repairing Liver Disease with mRNA
Pipeline Analysis
Patent Analysis
Findings
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Breakdown, by Disease Type
Takeaways
Hepatitis
Non-Alcoholic Fatty Liver Disease
Hepatocellular Carcinoma
Autoimmune Liver Diseases
Alcohol-induced Liver Disease (ALD)
Chronic Liver Disease
Other Liver-Related Diseases
Geographic Breakdown
Market Breakdown, by Region
Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa
Chapter 7 Competitive Intelligence
Takeaways
Market Ranking of Leading Companies
Strategic Analysis
Venture Funding and Investments
Chapter 8 Sustainability in the Liver Disease Treatment Industry: ESG Perspective
